Stefania Morganti, MD discusses ctDNA study

Name: Stefania Morganti, MD discusses ctDNA study
Uploaded: 2025-12-15T00:00:00+00:00
Description: Ultrasensitive detection of minimal residual disease using ctDNA can help predict the duration of response to HER2 targeted therapy in patients with metastatic breast cancer, according to a study presented by Stefani Morganti, MD, of Dana-Farber Cancer Institute.

Ultrasensitive detection of minimal residual disease using ctDNA can help predict the duration of response to HER2 targeted therapy in patients with metastatic breast cancer, according to a study presented by Stefani Morganti, MD, of Dana-Farber Cancer Institute. The data support tracking minimal residual disease to predict exceptional responses that last more than 3 years.

Published

December 15, 2025

Created by

Related Videos

Video

Rachel Freedman, MD discusses phase 2 ATOP study

Dana-Farber Cancer Institute's Rachel Freedman, MD, presents results from the phase 2 ATOP study showing older patients with HER2+ breast cancer receiving adjuvant T-DM1 had a favorable 5-year survival with manageable toxicity. ATOP is ...

Video

Erica Mayer, MD discusses results from TBCRC 56 study

Erica Mayer, MD, of Dana-Farber Cancer Institute shared results from TBCRC 56, showing presurgical treatment with a PARP inhibitor + anti-PD1 combo in patients with gBRCAm early triple-negative breast cancer resulted in a pCR rate of 50%. ...

Video

Paolo Tarantino, MD discusses the DATO - Base study

Paolo Tarantino, MD, of Dana-Farber Cancer Institute, presented new findings from the DATO-Base study examining treatment with the ADC Dato-DXd for women with leptomeningeal disease. Breast cancer is the most common cancer linked to this ...

Video

Ann Partride, MD discusses YES study

Breast cancer survivors who used a novel mobile health intervention to self-manage post-treatment symptoms were able to improve their quality of life and reduce the burden of common symptoms, according to results of the YES study presented ...